Cellectis S.A.
This information included in this report on Form 6-K, excluding the press release furnished as Exhibit 99.1 hereto, shall be deemed to be incorporated by reference in the Company’s registration statements on Form F-3 (No. 333-265826) and Form S-8 (Nos. 333-204205, 333-214884, 333-222482, 333-227717, 333-258514, 333-267760 and 333-273777), to the extent not superseded by documents or reports subsequently filed.
Management Update
On April 29, 2024, Bing Wang, the Chief Financial Officer of Cellectis S.A. (the “Company”), gave notice to the Company of his resignation, which became effective May 2, 2024. Mr. Wang will remain with the Company through May 17, 2024 to assist with the transition. Mr. Wang’s resignation was not related to any dispute or disagreement with the Company, including with respect to any matter relating to its accounting or financial reporting policies or practices.
Effective immediately, the Company appointed Arthur Stril, who currently serves as the Company’s Chief Business Officer, as the Company’s interim Chief Financial Officer, while the Company engages in a search for a permanent Chief Financial Officer.
Mr. Stril, 35, joined Cellectis in July 2018 as Vice President, Corporate Development, and was appointed Chief Business Officer in 2020. Mr. Stril serves on the board of directors of Primera Therapeutics, Inc. since May 2023, serving as a director designated by Cellectis Mr. Stril began his career at the European Commission’s Directorate-General for Competition, controlling global pharmaceutical mergers. He later became Head of the Hospital Financing Unit at the French Ministry of Health. Mr. Stril graduated from the École Normale Supérieure, Paris & Cambridge University, and holds a diploma in Immunotherapy from the Université Paris-Descartes. Mr. Stril is also a member of the French Corps des Mines and serves on the Board of Advisors of non-profit, Life Science Cares.
